Recent Research Analysts’ Ratings Changes for Quest Diagnostics (DGX)

Quest Diagnostics (NYSE: DGX) has recently received a number of price target changes and ratings updates:

• 7/13/2026 – Quest Diagnostics had its price target raised by Robert W. Baird from $232.00 to $236.00. They now have a “neutral” rating on the stock.
• 7/12/2026 – Quest Diagnostics was upgraded by Wall Street Zen from “hold” to “buy”.
• 7/9/2026 – Quest Diagnostics was upgraded by Weiss Ratings from “buy (b)” to “buy (b+)”.
• 6/28/2026 – Quest Diagnostics was downgraded by Wall Street Zen from “buy” to “hold”.
• 6/24/2026 – Quest Diagnostics was downgraded by Weiss Ratings from “buy (b+)” to “buy (b)”.
• 6/20/2026 – Quest Diagnostics was upgraded by Wall Street Zen from “hold” to “buy”.
• 6/9/2026 – Quest Diagnostics was upgraded by Weiss Ratings from “buy (b)” to “buy (b+)”.
• 5/30/2026 – Quest Diagnostics was downgraded by Wall Street Zen from “buy” to “hold”.
• 5/19/2026 – Quest Diagnostics was downgraded by Weiss Ratings from “buy (b+)” to “buy (b)”.

Quest Diagnostics Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, July 22nd. Stockholders of record on Wednesday, July 8th will be given a $0.86 dividend. The ex-dividend date of this dividend is Wednesday, July 8th. This represents a $3.44 dividend on an annualized basis and a dividend yield of 1.7%. Quest Diagnostics’s payout ratio is presently 38.01%.

Insider Buying and Selling

In other news, SVP Karthik Kuppusamy sold 8,147 shares of the firm’s stock in a transaction on Thursday, June 4th. The stock was sold at an average price of $200.00, for a total value of $1,629,400.00. Following the completion of the sale, the senior vice president owned 13,510 shares of the company’s stock, valued at $2,702,000. This trade represents a 37.62% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO J. E. Davis sold 10,000 shares of the company’s stock in a transaction dated Monday, June 1st. The shares were sold at an average price of $194.14, for a total value of $1,941,400.00. Following the transaction, the chief executive officer directly owned 132,423 shares in the company, valued at $25,708,601.22. This represents a 7.02% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.88% of the stock is owned by insiders.

Quest Diagnostics (NYSE: DGX) is a leading provider of diagnostic information services that supports clinical decision-making for patients, physicians and healthcare organizations. The company operates a network of clinical laboratories and patient service centers that perform a broad range of laboratory tests and diagnostic assays used in routine care, disease diagnosis, monitoring and screening.

Its services span core clinical laboratory testing, anatomic pathology, molecular and genomic diagnostics, infectious disease testing and toxicology.